AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas
- Collaboration to leverage AbbVie's expertise in biotherapeutic drug development and commercialization together with ADARx's proprietary RNA technology to advance next-generation siRNA therapies across neuroscience, immunology and oncology
NORTH CHICAGO, Ill. and SAN DIEGO, May 14, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and ADARx Pharmaceuticals, a late clinical-stage biotechnology company developing next-generation RNA therapeutics, today announced a collaboration and license option agreement to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, including neuroscience, immunology and oncology.
siRNA represents a class of molecules capable of regulating gene expression and protein production. Unlike traditional modalities such as antibodies and small molecules, siRNA regulates the expression of genes. These molecules are designed to prevent the production of disease-causing proteins by targeting the messenger RNA (mRNA) that encodes for such proteins.
The strategic collaboration will leverage ADARx's RNA discovery expertise and proprietary siRNA technology, which has the potential to enable sustained and precise mRNA silencing. AbbVie will contribute its expertise in antibody engineering, antibody drug conjugates (ADCs) and tissue delivery approaches as appropriate, to augment ADARx's discovery efforts.
'siRNA is a promising genetic medicine approach for silencing disease-causing genes, but challenges still remain in targeting and delivering siRNA effectively,' said Jonathon Sedgwick, Ph.D., senior vice president and global head, discovery research, AbbVie. 'We are very pleased to collaborate with ADARx, leveraging their proprietary RNA technology alongside our antibody, ADC, and therapeutic area research and development expertise to bring siRNA forward as a potential novel therapeutic modality alongside our other established approaches. Together, we're committed to developing innovative solutions for difficult-to-treat diseases across neuroscience, immunology and oncology.'
'This collaboration with AbbVie further validates the differentiated RNA technology that we have developed at ADARx and has the potential to unlock tremendous clinical and commercial potential across multiple disease areas. AbbVie's research and development expertise combined with its global commercial reach make them the ideal strategic collaborator to accelerate these programs for the potential benefit of patients worldwide,' said Zhen Li, Ph.D., co-founder, president and chief executive officer of ADARx. 'In addition to this strategic collaboration with AbbVie, ADARx continues to advance a deep pipeline of wholly-owned clinical-stage programs that span complement-mediated, cardiovascular and thrombotic diseases and various preclinical discovery programs including in obesity and neurodegeneration.'
Under the terms of the agreement, ADARx will receive a $335 million upfront payment and will be eligible to receive several billion dollars in additional contingent payments including option-related fees and milestone payments, as well as tiered royalties.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn,Facebook, Instagram, X (formerly Twitter) and YouTube.
About ADARx Pharmaceuticals
ADARx Pharmaceuticals, Inc. is a late clinical-stage biotechnology company dedicated to transforming cutting-edge science into next-generation RNA medicines across a wide range of therapeutic areas. Our goal is to control the expression of specific disease drivers with highly selective RNA targeted therapies, delivering life-changing treatments for patients with urgent unmet medical needs. We are focused on advancing and expanding a deep pipeline of highly potent, durable and selective RNA-targeted therapeutic candidates, initially developing our product candidates for the treatment of complement-mediated, genetic, cardiovascular, central nervous system and metabolic (obesity) diseases. Follow ADARx on LinkedIn.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words 'believe,' 'expect,' 'anticipate,' 'project' and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, 'Risk Factors,' of AbbVie's 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
View original content to download multimedia: https://www.prnewswire.com/news-releases/abbvie-and-adarx-pharmaceuticals-announce-collaboration-and-license-option-agreement-to-develop-next-generation-sirna-therapies-across-multiple-therapeutic-areas-302454426.html
SOURCE AbbVie
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Venture Global (VG) Extends Rally on $28-B LNG Facility
We recently published a list of . In this article, we are going to take a look at where Venture Global, Inc. (NYSE:VG) stands against other top-performing companies on Tuesday. Venture Global rallied by 8.37 percent on Tuesday to end at $17.04 apiece as investors resumed bargain-hunting following the commencement of its $28 billion liquefied natural gas (LNG) facility in Louisiana. Called the CP2 LNG, the facility will sit on a 1,150-acre site in Cameron Parish and is expected to be able to export at least 20 million tons of LNG per annum. According to the company, the new facility is also expected to generate 10,500 jobs, of which 7,500 will start during the construction, and 3,000 upon commercial operations. It is also expected to pay more than $4 billion in local property taxes once the LNG comes into full swing. A deep sea tanker vessel laden with liquified natural gas, contrailing a majestic stream of white smoke. Venture Global, Inc. (NYSE:VG) said it targets to kick off commercial operations in 2027. The facility is expected to make Venture Global, Inc. (NYSE:VG) the largest LNG exporter in the US, and the second largest in the world. Overall, VG ranks 2nd on our list of top-performing companies on Tuesday. While we acknowledge the potential of VG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
2 Volatile Stocks with Exciting Potential and 1 to Be Wary Of
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren't prepared. At StockStory, our job is to help you avoid costly mistakes and stay on the right side of the trade. That said, here are two volatile stocks with massive upside potential and one that could just as easily collapse. Rolling One-Year Beta: 1.18 With its iconic yellow machinery working on construction sites, Caterpillar (NYSE:CAT) manufactures construction equipment like bulldozers, excavators, and parts and maintenance services. Why Are We Hesitant About CAT? Core business is underperforming as its organic revenue has disappointed over the past two years, suggesting it might need acquisitions to stimulate growth Demand will likely fall over the next 12 months as Wall Street expects flat revenue Competitive supply chain dynamics and steep production costs are reflected in its low gross margin of 29% At $360 per share, Caterpillar trades at 18.6x forward P/E. Check out our free in-depth research report to learn more about why CAT doesn't pass our bar. Rolling One-Year Beta: 1.69 Founded in 2009 and a publicly traded company since 2017, Sea (NYSE:SE) started as a gaming platform and has since expanded to offer a variety of services such as e-commerce, digital payments, and financial services across Southeast Asia. Why Are We Backing SE? Paying Users are rising, meaning the company can increase revenue without incurring additional customer acquisition costs if it can cross-sell additional products and features Grip over its ecosystem is highlighted by its ability to grow engagement while increasing the average revenue per user by 11.7% annually Free cash flow margin expanded by 27.3 percentage points over the last few years, providing additional flexibility for investments and share buybacks/dividends Sea's stock price of $154.03 implies a valuation ratio of 40.9x forward EV/EBITDA. Is now the time to initiate a position? See for yourself in our in-depth research report, it's free. Rolling One-Year Beta: 1.20 Founded in 1952, Distribution Solutions (NASDAQ:DSGR) provides supply chain solutions and distributes industrial, safety, and maintenance products to various industries. Why Will DSGR Beat the Market? Market share has increased this cycle as its 17.8% annual revenue growth over the last two years was exceptional Incremental sales significantly boosted profitability as its annual earnings per share growth of 24.9% over the last two years outstripped its revenue performance Free cash flow margin grew by 3.8 percentage points over the last five years, giving the company more chips to play with Distribution Solutions is trading at $27.77 per share, or 16x forward P/E. Is now the right time to buy? Find out in our full research report, it's free. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
4 hours ago
- Business Insider
Morgan Stanley Weighs In on Boeing Stock Following Air India Crash
Boeing (NYSE:BA) marked a major milestone last month as the one-billionth passenger flew on its 787 Dreamliner – a big achievement for an aircraft that's only been in service for 14 years. Up until yesterday's tragic Air India crash in Ahmedabad, the 787 Dreamliner had built a strong reputation as a reliable workhorse for long-haul routes with an outstanding safety track record. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter It's important to note that this is a different aircraft from the Boeing 737 Max, which made headlines after the deadly crashes in Indonesia and Ethiopia in 2018 and 2019, claiming hundreds of lives. At this stage, there's no indication that Boeing is at fault for yesterday's incident in India. A clearer picture of what happened is expected to emerge once investigators retrieve the plane's black boxes – the onboard recorders that store critical flight data and cockpit audio. With BA shares taking a beating following the crash, Morgan Stanley analyst Kristine Liwag set out to get an idea of how investors feel about the stock right now. 'While our thoughts remain focused on those affected by the tragedy,' the 5-star analyst said, 'the feedback from investors is considerably less negative than after previous Boeing 737 MAX incidents.' On the positive side, given the strong safety history of the 787, many investors believe the stock's dip is an overreaction, especially as production of the 737 MAX continues to gain momentum. Footage of the incident appears to show a controlled descent, which could suggest that the cause may not be related to a systems failure on the aircraft itself. But the negative take is that incidents like this highlight the stock has a 'higher beta than in previous cycles,' i.e., heightened sensitivity to headlines. Boeing remains 'in the penalty box' due to prior incidents and with a range of pureplay aerospace alternatives available, many would prefer to remain on the sidelines for now. Plenty of questions remain for now. Some observers have noted that the aircraft appeared underpowered during its controlled descent. Investors are asking whether the problem could be related to the engines, maintenance or repair (MRO) issues, or possibly a bird strike. The Air India 787 is equipped with GE Aerospace engines. 'We will continue to monitor developments of the investigation,' Liwag summed up. All in, Liwag assigns an Equal-weight rating (i.e., Neutral) with a $200 price target, suggesting that the stock is fully valued at current levels. (To watch Liwag's track record, click here) While two other analysts also remain on the sidelines, they're outnumbered by 16 who are bullish on the stock. With just one dissenter issuing a Sell, the result is a Strong Buy consensus. Looking ahead, the average price target of $220.95 implies a potential upside of 10.5% over the next year. (See Boeing stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
